Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 1
2010 3
2011 2
2012 1
2013 2
2014 1
2015 6
2016 8
2017 12
2018 7
2019 12
2020 11
2021 20
2022 20
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35058323

101 results

Results by year

Filters applied: . Clear all
Page 1
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
Korsen JA, Gutierrez JA, Tully KM, Carter LM, Samuels ZV, Khitrov S, Poirier JT, Rudin CM, Chen Y, Morris MJ, Bodei L, Pillarsetty N, Lewis JS. Korsen JA, et al. Proc Natl Acad Sci U S A. 2022 Jul 5;119(27):e2203820119. doi: 10.1073/pnas.2203820119. Epub 2022 Jun 27. Proc Natl Acad Sci U S A. 2022. PMID: 35759660 Free PMC article.
First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Tendler S, et al. medRxiv [Preprint]. 2024 Jan 11:2024.01.10.24301109. doi: 10.1101/2024.01.10.24301109. medRxiv. 2024. PMID: 38260492 Free PMC article. Preprint.
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. Wang S, et al. Clin Cancer Res. 2021 Mar 1;27(5):1305-1315. doi: 10.1158/1078-0432.CCR-20-3310. Epub 2020 Dec 8. Clin Cancer Res. 2021. PMID: 33293372 Free PMC article.
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.
Sharma SK, Adumeau P, Keinänen O, Sisodiya V, Sarvaiya H, Tchelepi R, Korsen JA, Pourat J, Edwards KJ, Ragupathi A, Hamdy O, Saunders LR, Rudin CM, Poirier JT, Lewis JS, Zeglis BM. Sharma SK, et al. Bioconjug Chem. 2021 Jul 21;32(7):1255-1262. doi: 10.1021/acs.bioconjchem.1c00121. Epub 2021 Apr 9. Bioconjug Chem. 2021. PMID: 33835770 Free PMC article.
An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients.
Dietlein F, Kobe C, Vázquez SM, Fischer T, Endepols H, Hohberg M, Reifegerst M, Neumaier B, Schomäcker K, Drzezga AE, Dietlein M. Dietlein F, et al. J Nucl Med. 2022 Apr;63(4):573-583. doi: 10.2967/jnumed.121.262290. Epub 2021 Jul 29. J Nucl Med. 2022. PMID: 34326129 Free article.
PET imaging of new target CDK19 in prostate cancer.
Dai D, Yu J, Huang T, Li Y, Wang Z, Yang S, Li S, Li Y, Gou W, Li D, Hou W, Fan S, Li Y, Zhao Y. Dai D, et al. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3452-3464. doi: 10.1007/s00259-023-06277-2. Epub 2023 Jun 6. Eur J Nucl Med Mol Imaging. 2023. PMID: 37278941
101 results